老年患者出院时苯二氮䓬类药物暴露与6个月死亡率:是时候考虑减处方了吗?
该回顾性分析纳入急性老年病房连续入院的1375例患者(66-101岁),评估出院时苯二氮䓬(BZD)处方与6个月全因死亡率的关联。出院时使用BZD组(n=130)较未使用者(n=1066)6个月死亡率风险更高(HR 1.64;95%CI 1.14-2.37),而住院期间减处方组(n=179)死亡风险与未使用者相似(HR 0.97;95%CI 0.68-1.39)。结论提示出院时BZD处方与6个月死亡率升高相关,减处方可能减轻此超额风险。
要点
- 出院时使用BZD与6个月全因死亡率升高相关(HR 1.64;95%CI 1.14-2.37)。
- 住院期间减处方BZD者死亡风险与未使用者相似(HR 0.97;95%CI 0.68-1.39)。
- 住院可能是安全减处方BZD的时机。
核心结论
- 出院时BZD处方与6个月全因死亡率升高相关,而住院期间减处方可能减轻此超额风险。
研究设计与样本
- 回顾性分析前瞻性收集的连续入住急性老年病房患者数据,年龄66-101岁,入院时行老年综合评估。
- 采用多变量Cox回归模型评估出院时BZD处方(未使用、出院时使用、减处方)与6个月死亡率的关系。
- 共纳入1375例患者,中位年龄85.5岁(IQR 48-77),女性55%。
主要发现
- 出院时BZD组(n=130)较未使用者(n=1066)6个月全因死亡率风险更高(HR 1.64;95%CI 1.14-2.37)。
- 住院期间减处方组(n=179)死亡风险与未使用者相似(HR 0.97;95%CI 0.68-1.39)。
- 出院时BZD组较未使用者和减处方组更年轻(p=.029),衰弱(p=.031)、认知下降(p=.043)和院内谵妄(p<.001)患病率更低。
临床怎么用
- 对老年住院患者应评估BZD使用情况,考虑在住院期间安全减处方以降低出院后短期死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Benzodiazepines (BZDs) are commonly used in older populations despite their association with multiple adverse outcomes. However, the impact of continuing versus deprescribing BZDs during hospitalization on short-term mortality after discharge remains uncertain. This study aims to evaluate the association of BZD-use at hospital discharge with 6-month mortality and explore whether in-hospital deprescribing modifies mortality risk. METHODS: This is a retrospective analysis of prospectively collected data from patients (aged 66-101 years) consecutively admitted to an Acute Geriatric Unit. Upon admission, all patients underwent a Comprehensive Geriatric Assessment, including functional status, comorbidities, and medications review. A multivariable Cox regression model was used to evaluate the relationship between 6-month mortality and BZD prescription at hospital discharge (BZD nonusers, BZD at discharge, and BZD deprescribed). RESULTS: Overall, 1375 patients (median age: 85.5 [IQR: 48-77, 55% females]) were included. Following therapeutic reconciliation, the BZD at discharge group was younger (p = .029), had lower frailty (p = .031), cognitive decline (p = .043), and in-hospital delirium (p < .001) prevalence than the BZD nonusers and BZD deprescribed groups. The BZD at discharge group (n = 130) showed a higher risk of all-cause 6-month mortality compared to BZD nonusers (n = 1066) (HR: 1.64; 95% CI: 1.14-2.37). Conversely, patients in whom BZDs were deprescribed during hospitalization (n = 179) exhibited a similar mortality risk as nonusers (HR: 0.97; 95% CI: 0.68-1.39). CONCLUSIONS: BZDs prescription on hospital discharge was associated with an increased risk of 6-month mortality, whereas deprescription may mitigate this excess risk. Our data suggest that hospitalization may represent an opportunity to safely deprescribe BZDs in a controlled setting.
引用
- Bellelli F, Ferrara MC, Ornago AM, et al. Benzodiazepine exposure and 6-month mortality in older adults post-hospitalization: time to consider deprescribing? J Gerontol A Biol Sci Med Sci. 2026. PMID: 41284672. doi:10.1093/gerona/glaf260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。